Table 2.
Laboratory findings of cases
| Case 1 | Case 2 | Case 3 | ||
|---|---|---|---|---|
| WBC (μ/L) | Pretreatment* | 8900 | 9500 | 7650 |
| Posttreatment** | 4300 | 4270 | ||
| HGB (g/dl) | Pretreatment* | 13.4 | 11.9 | 12.2 |
| Posttreatment** | 12.1 | 10.9 | ||
| PLT (μ/L) | Pretreatment* | 245,000 | 342,000 | 267,000 |
| Posttreatment** | 158,000 | 145,000 | ||
| AST (U/L) | Pretreatment* | 34 | 32 | 45 |
| Posttreatment* | 53 | 67 | ||
| ALT (U/L) | Pretreatment* | 18 | 42 | 54 |
| Posttreatment** | 39 | 83 | ||
| Creatinine (mg/dl) | Pretreatment* | 0.8 | 1.2 | 0.98 |
| Posttreatment* | 0.91 | 1 | ||
| Bilirubin total (mg/dl) | Pretreatment* | 0.8 | 1 | 0.98 |
| Posttreatment** | 0.89 | 1 | ||
ALT alanine aminotransferase, AST aspartate aminotransferase, HGB hemoglobin, PLT platelet, WBC white blood cell, * before the start of the tyrosine kinase inhibitor, ** after the discontinue of tyrosine kinase inhibitor therapy. Case 2 treatment continues